MaxCyte (MXCT) Revenue & Revenue Breakdown
MaxCyte Revenue Highlights
Latest Revenue (Y)
$41.29M
Latest Revenue (Q)
$11.34M
Main Segment (Y)
Product sales
MaxCyte Revenue by Period
MaxCyte Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $41.29M | -6.72% |
| 2022-12-31 | $44.26M | 30.59% |
| 2021-12-31 | $33.89M | 29.52% |
| 2020-12-31 | $26.17M | 21.04% |
| 2019-12-31 | $21.62M | 29.72% |
| 2018-12-31 | $16.67M | 19.18% |
| 2017-12-31 | $13.98M | 13.98% |
| 2016-12-31 | $12.27M | 32.07% |
| 2015-12-31 | $9.29M | 29.67% |
| 2014-12-31 | $7.16M | 5.28% |
| 2013-12-31 | $6.80M | 34.50% |
| 2012-12-31 | $5.06M | - |
MaxCyte generated $41.29M in revenue during NA 2023, up -6.72% compared to the previous quarter, and up 247.72% compared to the same period a year ago.
MaxCyte Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $11.34M | -27.60% |
| 2023-12-31 | $15.67M | 95.71% |
| 2023-09-30 | $8.00M | -11.48% |
| 2023-06-30 | $9.04M | 5.44% |
| 2023-03-31 | $8.58M | -30.97% |
| 2022-12-31 | $12.42M | 16.73% |
| 2022-09-30 | $10.64M | 10.77% |
| 2022-06-30 | $9.61M | -17.08% |
| 2022-03-31 | $11.59M | 14.14% |
| 2021-12-31 | $10.15M | 0.13% |
| 2021-09-30 | $10.14M | 42.64% |
| 2021-06-30 | $7.11M | 9.44% |
| 2021-03-31 | $6.49M | -23.72% |
| 2020-12-31 | $8.51M | 25.90% |
| 2020-09-30 | $6.76M | 31.30% |
| 2020-06-30 | $5.15M | -10.30% |
| 2020-03-31 | $5.74M | -13.31% |
| 2019-12-31 | $6.62M | - |
| 2019-09-30 | $6.62M | 58.21% |
| 2019-06-30 | $4.19M | - |
| 2019-03-31 | $4.19M | -14.01% |
| 2018-12-31 | $4.87M | - |
| 2018-09-30 | $4.87M | 40.51% |
| 2018-06-30 | $3.46M | - |
| 2018-03-31 | $3.46M | -10.87% |
| 2017-12-31 | $3.89M | - |
| 2017-09-30 | $3.89M | 25.20% |
| 2017-06-30 | $3.11M | - |
| 2017-03-31 | $3.11M | -8.71% |
| 2016-12-31 | $3.40M | - |
MaxCyte generated $11.34M in revenue during Q1 2024, up -27.60% compared to the previous quarter, and up 91.29% compared to the same period a year ago.
MaxCyte Revenue Breakdown
MaxCyte Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Product sales | $18.60M | $27.73M | $20.79M |
| Other | $897.00K | $1.02M | $784.60K |
MaxCyte's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product sales (95.40%), and Other (4.60%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | $223.00K | $520.40K | $202.80K | $173.80K | $330.90K | $227.30K | $170.60K | $289.70K | $279.30K | $165.30K | $176.80K |
| Product sales | $5.36M | $8.39M | $5.42M | $4.79M | $7.43M | $6.93M | $6.81M | $6.57M | $7.23M | $5.44M | - |
| Product Sales | - | - | - | - | - | - | - | - | - | - | $4.04M |
MaxCyte's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product sales (96.01%), and Other (3.99%).
MaxCyte Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ITGR | Integer | $1.60B | $753.01M |
| CNMD | CONMED | $1.24B | $332.10M |
| ANIK | Anika Therapeutics | $166.66M | $41.92M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SRDX | Surmodics | $132.58M | $30.34M |
| SGHT | Sight Sciences | $81.06M | $21.37M |
| LUNG | Pulmonx | $68.67M | $20.78M |
| IRMD | IRadimed | $65.56M | $17.93M |
| NPCE | NeuroPace | $65.42M | $18.12M |
| MXCT | MaxCyte | $41.29M | $11.34M |
| CVRX | CVRx | $39.30M | $11.81M |
| OSA | ProSomnus | $27.65M | $7.46M |
| RPID | Rapid Micro Biosystems | $22.52M | $6.62M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
MXCT Revenue FAQ
What is MaxCyte’s yearly revenue?
MaxCyte's yearly revenue for 2023 was $41.29M, representing a decrease of -6.72% compared to 2022. The company's yearly revenue for 2022 was $44.26M, representing an increase of 30.59% compared to 2021. MXCT's yearly revenue for 2021 was $33.89M, representing an increase of 29.52% compared to 2020.
What is MaxCyte’s quarterly revenue?
MaxCyte's quarterly revenue for Q1 2024 was $11.34M, a -27.60% decrease from the previous quarter (Q4 2023), and a 32.25% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $15.67M, a 95.71% increase from the previous quarter (Q3 2023), and a 26.10% increase year-over-year (Q4 2022). MXCT's quarterly revenue for Q3 2023 was $8M, a -11.48% decrease from the previous quarter (Q2 2023), and a -24.79% decrease year-over-year (Q3 2022).
What is MaxCyte’s revenue growth rate?
MaxCyte's revenue growth rate for the last 3 years (2021-2023) was 21.81%, and for the last 5 years (2019-2023) was 90.97%.
What are MaxCyte’s revenue streams?
MaxCyte's revenue streams in c 23 are Product sales, and Other. Product sales generated $18.6M in revenue, accounting 95.40% of the company's total revenue, down -32.93% year-over-year. Other generated $897K in revenue, accounting 4.60% of the company's total revenue, down -11.93% year-over-year.
What is MaxCyte’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of MaxCyte was Product sales. This segment made a revenue of $18.6M, representing 95.40% of the company's total revenue.